COVID-19 Letter to the Editor Volume 12, Issue 22 pp 22370—22389
Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer
Figure 1. The analyses of gene variation and epigenetics of CTSL/B and ACE2 in pan-cancer. (A) The distribution of differential expression of CTSL/B in 31 types of cancers and adjacent tissues based on TCGA and Genotype-Tissue Expression (GTEx) data (GEPIA). (B) The exhibition of tumors upregulating CTSL/B and ACE2, respectively. (C) The overlap of tumors overexpressing ACE2, CTSL/B using venny 2.0.2. (D) The significant difference analysis of CTSL/B in PAAD and STAD. (E) The mutation and CNA distribution of CTSL/B in pan-cancer (cBioportal). (F) The statistical difference graphs of DNA methylation for CTSB/L in PAAD (DiseaseMeth version 2.0). p<0.05 was regarded as significant.